



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
CIN No. L74899DL1978PLC009181

Date: February 12th, 2021

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001	To, The Manager- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Script Code: 507789	Symbol: JAGSNPHARM

SUBJECT:- OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON FEBRUARY 12TH, 2021

Dear Sir,

We wish to inform you that the Board of Directors of the Company at their meeting held today, (i.e., Friday, the 12th Day of February, 2021), have inter alia, approved and taken on record the followings:

1. Un-Audited Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2020;
2. Limited Review Report for the Quarter and Nine Months ended 31st December, 2020;

Kindly take the above on record & oblige.

For JAGSONPAL PHARMACEUTICALS LIMITED




Nandita Singh
Company Secretary & Compliance Officer



LIMITED REVIEW REPORT

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

1. We have reviewed the accompanying statement of Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter and Nine Months ended 31st December, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For H.L. Bansal & Co.
Firm Registration Number: 08563N
Chartered Accountants



H. L. Bansal
Partner

Membership Number: 086990

Date: 12th February, 2021
Place: New Delhi

UDIN - 21086990 AAAABD 4971



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
 CIN No. L74899DL1978PLC009181

Statement of Standalone Unaudited Financial Results for the Quarter ended 31.12.2020 and Nine Month Ended 31.12.2020

Particulars	Standalone						Rs. in lacs
	Quarter Ended			Nine Month Ended			12 Months
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	Year Ended	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Income from operations							
a Gross Sales/Revenue from Operations	5710.43	5635.27	4201.04	14510.91	12905.03	15856.78	
b Other Operating Income	0.00		0.00	0.00	0.00	0.00	
Total Income from operations	5710.43	5635.27	4201.04	14510.91	12905.03	15856.78	
2 Other Income	53.48	41.35	65.08	173.28	176.58	252.62	
3 Total Income [1+2]	5763.91	5676.62	4266.12	14684.19	13081.61	16109.40	
4 Expenses							
a Cost of materials consumed	1172.94	1090.61	1244.12	2703.75	3173.47	3678.48	
b Purchases of stock-in-trade	1403.74	933.35	535.02	2571.83	1471.23	1815.19	
c Changes in inventories of finished goods, work in progress and Stock in trade	-47.90	765.48	-380.60	1297.27	191.61	124.99	
d Employee benefits expenses	1533.20	1565.80	1461.64	4280.98	4023.05	5037.42	
e Finance Cost	13.56	11.69	10.12	38.34	36.70	51.41	
f Depreciation and amortisation expense	27.43	27.46	25.95	82.34	81.28	112.98	
g Other expenses	1000.18	796.60	1084.46	2260.76	3314.77	4347.45	
Total expenses	5103.15	5190.99	3980.71	13235.27	12292.11	15167.92	
5 Profit before exceptional items and taxes (3-4)	660.76	485.63	285.41	1448.92	789.50	941.48	
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	
7 Profit before tax [5-6]	660.76	485.63	285.41	1448.92	789.50	941.48	
8 Tax expense	117.73	84.75	57.09	252.98	157.90	154.40	
9 Net Profit for the period [7-8]	543.03	400.88	228.32	1195.94	631.60	787.08	
10 Other Comprehensive Income							
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00	0.00	
12 Total Comprehensive Income [9+11]	543.03	400.88	228.32	1195.94	631.60	787.08	
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90	
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)							
a Basic (Rs.)	2.07	1.53	0.87	4.57	2.41	3.00	
b Diluted (Rs.)	2.07	1.53	0.87	4.57	2.41	3.00	

Notes

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 12, 2021. The results have been subjected to Unaudited review by statutory Auditors of the Company.
2. In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
3. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
4. The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
6. The revenue for the quarter ended 31-12-2020, is reported net of GST.
7. Provision for taxation includes provision for current tax.



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

Place : New Delhi
Date : 12-02-2021

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953